- 1 High content image analysis in routine diagnostic histopathology predicts outcomes
- 2 in HPV-associated oropharyngeal squamous cell carcinomas
- 3 Jonas Hue<sup>a, \*</sup>, Zaneta Valinciute<sup>a</sup>, Selvam Thavaraj<sup>a</sup> & Lorenzo Veschini<sup>a, \*</sup>
- <sup>4</sup> <sup>a</sup> Faculty of Dentistry, Oral and Craniofacial Sciences, King's College London, United
- 5 Kingdom
- <sup>6</sup> \* Corresponding authors at: Faculty of Dentistry, Oral and Craniofacial Sciences, King's
- 7 College London, Guy's Hospital, Great Maze Pond, London, SE1 1UL, United Kingdom (J.
- 8 Hue and L. Veschini).
- 9 Email addresses: jonas\_hue@hotmail.com (J. Hue) and lorenzo.1.veschini@kcl.ac.uk (L.
- 10 Veschini).
- 11 Word count: 3247

# 12 Conflict of Interest

13 The authors have no conflicts of interest to declare.

#### 14 Abstract

15 Objective: Routine haematoxylin and eosin (H&E) photomicrographs from human 16 papillomavirus-associated oropharyngeal squamous cell carcinomas (HPV+OpSCC) contain 17 a wealth of prognostic information. In this study, we set out to develop a high content image 18 analysis workflow to quantify features of H&E images from HPV+OpSCC patients to identify 19 prognostic features which can be used for prediction of patient outcomes. 20 Methods: We have developed a dedicated image analysis workflow using open-source 21 software, for single-cell segmentation and classification. This workflow was applied to a set 22 of 567 images from diagnostic H&E slides in a retrospective cohort of HPV+OpSCC patients 23 with favourable (n = 29) and unfavourable (n = 29) outcomes. Using our method, we have 24 identified 31 quantitative prognostic features which were quantified in each sample and used 25 to train a neural network model to predict patient outcomes. The model was validated by k-26 fold cross-validation using 10 folds and a test set. 27 Results: Univariate and multivariate statistical analyses revealed significant differences 28 between the two patient outcome groups in 31 and 16 variables respectively (P<0.05). The 29 neural network model had an overall accuracy of 78.8% and 77.7% in recognising 30 favourable and unfavourable prognosis patients when applied to the test set and k-fold 31 cross-validation respectively. 32 Conclusion: Our open-source H&E analysis workflow and model can predict HPV+OpSCC 33 outcomes with promising accuracy. Our work supports the use of machine learning in digital 34 pathology to exploit clinically relevant features in routine diagnostic pathology without 35 additional biomarkers. 36 **Keywords:** Human Papillomavirus, Oropharyngeal Squamous Cell Carcinoma, 37 Oropharyngeal Cancer, Oral And Maxillofacial Pathology, Head And Neck Cancer,

38 Computer-assisted Image Analysis, Machine Learning, Neural Network Models, Tumor

39 Microenvironment, Single-cell Analysis.

## 40 Introduction

41	The worldwide incidence of HPV-associated oropharyngeal squamous cell carcinoma
42	(HPV+OpSCC) has been steadily increasing over the past two decades and is projected to
43	continue to rise over the next twenty years <sup>1,2</sup> . In parallel with the alarming incidence rise of
44	this disease, it is now established that HPV+OpSCCs have on average better survival
45	outcomes compared to site and stage-matched HPV negative counterparts <sup>3</sup> . The robust
46	evidence of more favourable outcomes in HPV+OpSCC has led to recent calls for treatment
47	de-escalation in this group of patients, with several clinical trials currently in progress <sup>4</sup> .
48	However, it is also recognised that not all HPV+OpSCC patients will benefit from treatment
49	de-escalation since a small but significant proportion of these tumours demonstrate disease
50	progression or recurrence similar to HPV-independent oropharyngeal squamous cell
51	carcinoma (HPV-OpSCC) <sup>5-7</sup> . Therefore, accurately predicting patients who will benefit from
52	treatment de-escalation is key to improving their quality of life while at the same time
53	ensuring optimal radical dose regimens in cases likely to progress or recur.
54	Several potential prognostic factors in HPV+OpSCC have recently been described, including
54 55	Several potential prognostic factors in HPV+OpSCC have recently been described, including tumour cytomorphology <sup>8,9</sup> , density <sup>10</sup> and immunoprofile of tumour infiltrating lymphocytes
55	tumour cytomorphology <sup>8,9</sup> , density <sup>10</sup> and immunoprofile of tumour infiltrating lymphocytes
55 56	tumour cytomorphology <sup>8,9</sup> , density <sup>10</sup> and immunoprofile of tumour infiltrating lymphocytes (TILs) <sup>11</sup> , plasma cell <sup>12</sup> and macrophage infiltrates <sup>12</sup> , as well as gene methylation <sup>13</sup> and
55 56 57	tumour cytomorphology <sup>8,9</sup> , density <sup>10</sup> and immunoprofile of tumour infiltrating lymphocytes (TILs) <sup>11</sup> , plasma cell <sup>12</sup> and macrophage infiltrates <sup>12</sup> , as well as gene methylation <sup>13</sup> and genomic heterogeneity <sup>14</sup> . Evaluating these biomarkers is a promising strategy to select
55 56 57 58	tumour cytomorphology <sup>8,9</sup> , density <sup>10</sup> and immunoprofile of tumour infiltrating lymphocytes (TILs) <sup>11</sup> , plasma cell <sup>12</sup> and macrophage infiltrates <sup>12</sup> , as well as gene methylation <sup>13</sup> and genomic heterogeneity <sup>14</sup> . Evaluating these biomarkers is a promising strategy to select patients for treatment de-escalation in clinical trials. However, evaluation of biomarkers often
55 56 57 58 59	tumour cytomorphology <sup>8,9</sup> , density <sup>10</sup> and immunoprofile of tumour infiltrating lymphocytes (TILs) <sup>11</sup> , plasma cell <sup>12</sup> and macrophage infiltrates <sup>12</sup> , as well as gene methylation <sup>13</sup> and genomic heterogeneity <sup>14</sup> . Evaluating these biomarkers is a promising strategy to select patients for treatment de-escalation in clinical trials. However, evaluation of biomarkers often requires complex laboratory testing and interpretation which is costly, lack widespread
55 56 57 58 59 60	tumour cytomorphology <sup>8,9</sup> , density <sup>10</sup> and immunoprofile of tumour infiltrating lymphocytes (TILs) <sup>11</sup> , plasma cell <sup>12</sup> and macrophage infiltrates <sup>12</sup> , as well as gene methylation <sup>13</sup> and genomic heterogeneity <sup>14</sup> . Evaluating these biomarkers is a promising strategy to select patients for treatment de-escalation in clinical trials. However, evaluation of biomarkers often requires complex laboratory testing and interpretation which is costly, lack widespread availability and is overall beyond the scope of routine diagnostic histopathology services.
55 56 57 58 59 60 61	tumour cytomorphology <sup>8,9</sup> , density <sup>10</sup> and immunoprofile of tumour infiltrating lymphocytes (TILs) <sup>11</sup> , plasma cell <sup>12</sup> and macrophage infiltrates <sup>12</sup> , as well as gene methylation <sup>13</sup> and genomic heterogeneity <sup>14</sup> . Evaluating these biomarkers is a promising strategy to select patients for treatment de-escalation in clinical trials. However, evaluation of biomarkers often requires complex laboratory testing and interpretation which is costly, lack widespread availability and is overall beyond the scope of routine diagnostic histopathology services. Furthermore, the reason for unfavourable clinical outcomes is likely to be multifactorial <sup>15</sup> and
<ol> <li>55</li> <li>56</li> <li>57</li> <li>58</li> <li>59</li> <li>60</li> <li>61</li> <li>62</li> </ol>	tumour cytomorphology <sup>8,9</sup> , density <sup>10</sup> and immunoprofile of tumour infiltrating lymphocytes (TILs) <sup>11</sup> , plasma cell <sup>12</sup> and macrophage infiltrates <sup>12</sup> , as well as gene methylation <sup>13</sup> and genomic heterogeneity <sup>14</sup> . Evaluating these biomarkers is a promising strategy to select patients for treatment de-escalation in clinical trials. However, evaluation of biomarkers often requires complex laboratory testing and interpretation which is costly, lack widespread availability and is overall beyond the scope of routine diagnostic histopathology services. Furthermore, the reason for unfavourable clinical outcomes is likely to be multifactorial <sup>15</sup> and individual biomarkers could fail to fully capture this complexity. Accounting for multiple
<ol> <li>55</li> <li>56</li> <li>57</li> <li>58</li> <li>59</li> <li>60</li> <li>61</li> <li>62</li> <li>63</li> </ol>	tumour cytomorphology <sup>8,9</sup> , density <sup>10</sup> and immunoprofile of tumour infiltrating lymphocytes (TILs) <sup>11</sup> , plasma cell <sup>12</sup> and macrophage infiltrates <sup>12</sup> , as well as gene methylation <sup>13</sup> and genomic heterogeneity <sup>14</sup> . Evaluating these biomarkers is a promising strategy to select patients for treatment de-escalation in clinical trials. However, evaluation of biomarkers often requires complex laboratory testing and interpretation which is costly, lack widespread availability and is overall beyond the scope of routine diagnostic histopathology services. Furthermore, the reason for unfavourable clinical outcomes is likely to be multifactorial <sup>15</sup> and individual biomarkers could fail to fully capture this complexity. Accounting for multiple variables including cytomorphology, intratumoural morphologic heterogeneity, together with

67 Within this context, we developed an automated workflow for quantitative high content image 68 analysis (HCA) of diagnostic haematoxylin and eosin (H&E)-stained sections of 69 HPV+OpSCC using open-source software with little computational requirements. We 70 measured TILs, stromal plasma cells, tumour nuclear features, morphological heterogeneity 71 of tumour cells and the spatial relationship between TILs and tumour cells. The overall aim 72 of the current study was to assess the value of HCA to identify potentially prognostic 73 features in routine H&E slides and to develop a neural network model based on our features 74 to predict outcomes in HPV+OpSCC patients.

75

## 76 Patients and Methods

#### 77 Patient Selection

78 Cases were selected from a previously characterised cohort of 231 patients HPV+OpSCC 79 patients treated at Guy's & St Thomas' NHS Foundation Trust between January 2005 and December 2017<sup>10</sup>. HPV positivity was defined as strong and diffuse nuclear and cytoplasmic 80 81 staining for p16 immunohistochemistry and diffuse or punctate signal by HPV DNA in-situ 82 hybridisation according to current guidelines<sup>16</sup>. All 29 patients with unfavourable outcomes 83 (UO), (defined as death from disease or local, regional, or distant recurrence within 5 years) 84 were identified and included in the current study. An additional 29 patients with favourable 85 outcomes (FO), (defined as disease-free at 5 years) were randomly selected using a random 86 number generator. All patients were anonymised prior to image acquisition and data 87 analysis. A further 15 patients for a workflow development group were randomly selected 88 from the remaining cohort after excluding the 58 UO and FO patients. This group was used 89 to develop the image analysis workflow to ensure the workflow was robust enough to handle 90 previously unseen images. All patient data was handled in compliance with the UK Data 91 Protection Act. The Outer North East London Research Ethics Committee of the National 92 Research Ethics Service gave ethical approval for this work.

#### 93 Image Acquisition

94 Ten separate representative digital images from archival diagnostic H&E-stained slides were 95 acquired at 100x optical magnification for each patient. Where possible, each image 96 contained approximately 70% tumour and 30% stroma. All images were assessed by a 97 specialist head and neck pathologist and deemed representative of the overall diagnostic 98 slide. A total of 567 images were acquired across the 58 patients with some patients having 99 less than ten images due to the small biopsy size.

## 100 Image Analysis

101 A dedicated image analysis workflow was developed to segment and classify individual cells

102 and cell objects in the H&E sections (Fig 1A). See Table 1 for a summary of the software

103 used and their respective functions. To develop the image analysis workflow, 15 patients

104 were randomly selected after excluding the 58 aforementioned UO and FO patients.

105 Processing was automated with scripts in QuPath and macros in ImageJ (publicly available

106 on GitHub at https://github.com/jonashue1/HPV-OpSCC-Machine-Learning).

Image pre-processing was performed in ImageJ<sup>17</sup> by applying an unsharp mask to all 107 108 images. ImageJ was also used to empirically increase the minimum pixel values for faded 109 slides from 7 patients in a supervised manner. All images were then exported to QuPath<sup>18</sup> 110 where machine learning (ML) was used to overcome the issue of stain variability of H&E 111 images with an artificial neural network pixel-classifier. The pixel-classifier identified pixels of 112 interest belonging to cells and cell objects for easier downstream object-based segmentation 113 (Fig 1A2). To further improve segmentation of nuclei, Stardist was utilised as an ImageJ 114 plugin employing a pre-trained model based on H&E images<sup>19</sup> (Fig 1A3). Elaborated images were obtained and imported directly to CellProfiler<sup>20</sup> for object-level segmentation (cells, 115 116 tumour nuclei and nucleoli, TILs, and plasma cells) (Fig 1A4). Finally, we used an ML-based 117 object classifier tool (CellProfiler Analyst<sup>21</sup>) to further discriminate cells of interest on the 118 basis of object measurements (Fig 1A5). The various cells are classified with this model and

- 119 quantified by CellProfiler. The cell classification was qualitatively reviewed by a specialist
- 120 head and neck pathologist (see Fig 1B for examples of the cell classification).
- 121 An index of stromal TILs (TIL index) was calculated to attempt to account for the variation of
- 122 tumour and stromal areas in each image.

$$TIL \ Index = \ No. \ of \ Stromal \ TILs \times \frac{Tumour \ Area}{Stromal \ Area}$$

- 123 Tumour nuclear features for texture, granularity and morphology were measured in
- 124 CellProfiler. The cohesiveness of the tumour was measured by the distance of each tumour
- 125 cell to their first and second closest neighbours. The number of neighbours each tumour cell
- 126 had was also quantified.
- 127 Intratumoural heterogeneity for nuclear morphological, textural and spatial features was
- 128 quantified by the spread of the data for each respective variable and taken as the variance of
- 129 the measurement per field of view. All measurements were exported to an SQLite database
- 130 and imported into R.
- 131 The image analysis workflow took under 50 hours to process 567 images from 58 patients,
- 132 making measurements of more than 800 000 individual tumour and stromal cells with a
- 133 standard 8GB RAM computer. This averaged a processing time of approximately 51.7
- 134 minutes per patient.
- 135 Identifying Prognostic Features
- 136 Statistical analysis was performed in R using univariate Wilcoxon's rank sum test and
- 137 multivariate logistic regression (LR) to identify variables that had a statistically significant
- 138 difference between patients with unfavourable and favourable outcomes. Statistical
- 139 significance was accepted at P < 0.05.

140 Prognostic Model

- 141 The prognostic features identified were used to train a neural network to predict patient
- 142 outcomes in our cohort of patients. The 567 images were split into a training and test set
- 143 with 80% (n = 457) and 20% (n = 110) of images respectively. The neural network was
- 144 designed with 4 hidden layers and 16, 8, 8 and 4 nodes in each respective layer. The model
- 145 was further validated with a k-fold cross validation using 10 folds.

#### 146 **Results**

- 147 The clinicopathologic features of the patient cohort are summarised in Table 2.
- 148 Image Analysis Workflow

149 An image analysis workflow was successfully developed to segment and classify the various

150 cell types within each biopsy. Fig 1B shows examples of the workflow being used to quantify

- 151 various biopsy features.
- 152 Statistical analysis of selected features reveals prognostic features

153 Quantitative measurements of the variables considered in this study are summarised in 154 Table 3. Univariate analysis revealed that 31 variables (Fig 2) in our study were significantly 155 different in FO versus UO patients demonstrating the value of these factors for patient 156 stratification. TILs, regardless of tissue compartment, were more abundant in FO patients 157 than UO patients. Plasma cell counts were also higher in the FO group with a median of 65 158 (97.25) versus 27 (53.5). Form factor, eccentricity, compactness cell area and perimeter are 159 used to quantify cytomorphology. In general, FO patients had rounder and less eccentric 160 cells, while cell area was not significantly different between the two groups. FO patients also 161 had tumour cells packed closer to one another with shorter distances between their 162 neighbours. FO patients had higher values for various texture and granularity measurements 163 of tumour nuclei. Intratumoural heterogeneity was significantly greater in UO patients for 164 most measurements of texture, granularity, cytomorphology and spatial packing.

165 Overall, the heat map (Fig 2) reveals clustering of patients by outcomes. Two broad clusters 166 appear evident from the heat map with most of FO patients clustering at the top. In general, 167 these patients had a stronger immune infiltrate and low intratumoural heterogeneity. On the 168 other hand, UO patients clustered at the bottom, exhibiting generally low immune infiltrate 169 and higher intratumoural heterogeneity. Our analysis also reveals inter-tumour homogeneity 170 for various measurements in FO patients. Conversely, patients with UO have greater inter-171 tumour heterogeneity. When these patients do not strictly follow trends, predicting their 172 outcomes becomes increasingly difficult. Taken individually, none of the variables were 173 predictive of the outcome as shown by the inter- and intratumoural variability. Therefore, we 174 proceeded to analyse our data through multivariate LR and machine learning tools. 175 Multivariate analysis and machine learning predicts patient outcomes 176 Results of the multivariate LR are summarised in Table 3. Fig 3A shows boxplots of selected 177 variables that were statistically significant on both univariate and multivariate analyses. 178 We trained a neural network (NN) to use all statistically significant variables to predict patient 179 outcomes. Fig 3B shows the NN applied to the test set of images and a clear split between 180 the UO and FO groups. The model had an overall accuracy of 78.76%. In predicting patients 181 with FO, it had a sensitivity of 72.13% and a specificity of 86.54%. The model had a Kappa 182 statistic of 0.579, indicating a good model considering the difficulty of the task<sup>22</sup>. 183 Furthermore, a k-fold cross-validation was used to validate the model using 10 folds. This 184 revealed similar results when the model was applied to the test set with an average overall 185 accuracy of 77.72% and Kappa statistic of 0.552. The average sensitivity and specificity for 186 the favourable outcome group was 77.17% and 78.12% respectively.

187

188 Discussion

189 Recent years have seen a growing number of calls to de-intensify treatment regimens for 190 HPV+OpSCC since the majority of these patients demonstrate better overall and disease-191 specific survival compared to HPV-unrelated counterparts. However, a significant proportion 192 of patients with HPV+OpSCC still exhibit UO following radical treatment for whom de-193 intensification would be inappropriate<sup>5</sup>. While various biomarkers have proposed to have 194 prognostic value in HPV+OpSCC, none of these have been validated for routine clinical 195 practice or are under investigation to stratify patients in de-escalation trials. Against this 196 background, routine diagnostic H&E sections contain a wealth of data which can be 197 exploited for prognostic purposes without the need for additional laboratory tests which may 198 be costly and delay the initiation of treatment. However, assessment of H&E features by 199 pathologists is challenging, subject to bias and lacks reproducibility. For example, in Fig 1C, 200 representative photomicrographs from patients with FO (C1) and UO (C2) show similar 201 histological features, illustrating the challenges of subjective prognostication, even to an 202 experienced pathologist. By contrast, HCA and various implementations of machine learning 203 algorithms have been successfully employed to evaluate histology images in cancers<sup>23</sup>, but 204 these tools are currently unavailable for OpSCC. Therefore, in the present work we aimed at 205 building an automated tool to analyse large numbers of histological images accurately and 206 reproducibly, to demonstrate the value of our tool to detect and measure prognostic features, 207 and to predict patient outcomes in HPV+OpSCC.

208 Our work has identified various prognostic factors, some of which corroborates with

209 established findings in the literature while others are fairly novel. TILs have been shown to

210 be a prognostic factor in HPV+OpSCCs<sup>10</sup>. However, many studies employ a semi-

211 quantitative method of assessment with suboptimal inter-observer agreement and

reproducibility. A digital workflow is able to perform the exact same steps with each round of

analysis. Furthermore, such methods of assessment are time-consuming and labour-

214 intensive for the quantification of a single prognostic feature. Many patients exhibit a strong

215 immune infiltrate consisting of various immune cell types like plasma cells and TILs and this

complicates the current proposed methods of TIL quantification by estimating the area of stroma covered by TILs<sup>24</sup>. Furthermore, to our best knowledge, previous studies have not investigated the prognostic value of TILs in different tissue compartments, stromal versus intratumoural in HPV+OpSCC. Our various measurements of TILs have all shown to be strong prognostic factors. The implementation of the TIL index to account for variation in area of tumour to stroma resulted in a high statistical significance, improving our confidence in the measurement of this variable as a prognostic feature.

223 We found that stromal plasma cells were increased in patients with FO. Few studies have 224 investigated the role of plasma cells in the stromal component of HPV+OpSCCs and many 225 studies choose to ignore this subset of immune cells. However, some recent work has suggested plasma cells may exhibit resistance to radiotherapy over other B cells<sup>25</sup>. This may 226 227 have an impact on the antigen-specific antibody response to the tumour but further studies 228 elucidating the biological role of plasma cells in HPV+OpSCCs are required. Another study 229 looking at a plasma cell marker, immunoglobulin J polypeptide (IGJ), found that patients with higher IGJ had better disease-specific and overall survival<sup>12</sup>. While none of these studies 230 231 directly quantify plasma cells in H&E slides, they are in agreement with the trends we have 232 observed, and we show an alternative method to guantify plasma cells as a prognostic 233 feature without the transcriptomics or flow cytometry used in these studies. 234 Our workflow has managed to automate the single-cell quantification of anisonucleosis and

nuclear pleomorphism from several morphological measurements of tumour nuclei.
Previously, Lewis and colleagues reported an association between cellular anaplasia and
UO in HPV+OpSCCs<sup>26</sup>. Similarly, our results revealed patients with FO tended to have
rounder, less eccentric nuclei with smaller perimeters for the same area. Interestingly, while
the size of the nuclei was not significantly different between the two groups when measured
across thousands of nuclei, there was greater heterogeneity in the sizes of nuclei from UO
patients. This highlights the importance of intratumour heterogeneity as prognostic feature,

while the average of a measured variable may not be prognostic itself, the degree of spread

of the data within the quantified variable may be prognostic. UO patients had greater
intratumour heterogeneity in all 5 morphological measurements with 4 of them being
statistically significant by univariate analysis. To the best of our knowledge, quantification of
morphological intratumour heterogeneity has not been reported in the literature for
HPV+OpSCCs. This morphologic heterogeneity may represent an underlying genetic
heterogeneity in patients with UO, although further investigations are required to identify this
potential link.

250 A previous study by Ali and colleagues found that the spatial distribution and tumour nuclear

251 clustering was helpful in developing a predictive model of outcome in p16+ OpSCC

252 patients<sup>27</sup>. Similarly, we found that tumour nuclei from FO patients clustered closer to one

another as evidenced by higher number of neighbours and shorter first and second

254 neighbour distances. Furthermore, this pattern of spatial distribution was more homogenous

255 across the tumour for these FO patients. In non-HPV head and neck cancer, Delides and

colleagues quantified the heterogeneity of spatial distribution of laryngeal carcinoma by

257 measuring fractal dimensions<sup>28</sup>. Their work revealed that patients with poor outcomes had

258 neoplastic tissues that exhibited greater spatial irregularities.

259 Texture features quantified by image analysis have been used to prognosticate patients from 260 various cancer types. However, most studies measure textural features across the whole 261 image rather than within the individual nuclei, making it more difficult to elucidate their 262 biological significance. However, a study in breast cancer measured nuclear textural 263 features as a way to quantify DNA arrangement and found some texture measurements to improve the prognostication of patients<sup>29</sup>. Our study similarly found several texture and 264 265 granularity measurements within tumour nuclei to be prognostic and these features were 266 used to train our neural network model. Furthermore, we attempted to quantify distinct 267 nucleoli by searching for small, round objects within tumour nuclei. We found patients with 268 more nucleoli had better outcomes and as expected, these patients also had higher textural 269 and granularity values. This shows that while textural features can be difficult to interpret and ascribe biological significance to, they may be used to measure visual and biologically
relevant features within tumour cells. The presence and size of nucleoli have been reported
to carry both favourable and unfavourable prognosis in different cancer types<sup>30,31</sup>. Hence, we
interpret these findings with caution as it is currently not possible to determine the quality of
function of these nucleoli through image analysis alone.

275 Overall, our model captures all these features providing ground to build predictive statistical 276 models able to account for multiple prognostic features. Importantly, most of our selected 277 features have direct link with known biological counterparts, thus our HCA tools could be 278 used to develop new mechanistic hypotheses and computational models to complement and 279 enrich statistical inference. Nonetheless, none of these prognostic features are able to 280 predict patient outcomes on their own. There is significant inter-sample heterogeneity as 281 visualised in the heat map (Fig 2.) and despite the patients generally clustering by outcome, 282 they do not form groups that are easily separable. Hence, AI tools that take into account 283 multiple variables and large quantities of data are required to make accurate predictions of 284 patient prognoses. In this study, we have shown the usefulness of such tools and their ability 285 to achieve promising accuracies.

286 We show that the development of a predictive statistical model is possible by automated 287 quantification of routine H&E biopsies without staining for additional biomarkers or other 288 diagnostics. This is also done in a timely manner, avoiding delays to treatment initiation. The 289 entire workflow averaged under an hour of processing time per patient on a standard 290 computer, without the need to purchase dedicated computational resources. While we have 291 developed a workflow that does not require the additional time and cost involved in obtaining 292 whole-slide scans, our platform is also easily adaptable to analyse whole-slide scans which 293 might be advantageous in a diagnostic digital pathology service context. Such a workflow 294 using free-to-use, open-source software is easy to implement, without high financial barriers 295 to entry. This allows a digital pathology workflow to be implemented even in developing 296 countries to improve diagnostic capabilities.

#### 297 Conclusion

- 298 In summary, we built a single-cell quantitative image analysis workflow to analyse
- 299 HPV+OpSCC H&E slides to identify prognostic factors and quantify their heterogeneity
- 300 within the tumour. We have shown that some of these measures are predictive in their own
- 301 right, and that their variance within a tumour can itself be prognostic and contribute strongly
- 302 to the accuracy of predictive models.
- 303 Our open-source high content analysis workflow on routine H&E slides and statistical
- 304 modelling can aid prognostication of HPV+OpSCCs with promising accuracy. Our work
- 305 supports the use of machine learning-powered high content analysis followed by statistical
- 306 modelling in digital pathology to exploit clinically relevant features in routine diagnostic
- 307 pathology without additional laboratory diagnostics.

### 308 Acknowledgements

- 309 This research did not receive any specific grant from funding agencies in the public,
- 310 commercial, or not-for-profit sectors.

### **Declaration of Competing Interests**

312 The authors have no competing interests to declare.

#### 313 **Figure Captions**

- Figure 1. (A1-6) Overview of the image analysis workflow. H&E images (A1) analysed by
- 315 ML-aided software. QuPath (A2) for initial pixel-level classification. Stardist (A3) refined
- 316 nuclear segmentation for clustered objects. CellProfiler (A5). Neural network model to
- 317 predict outcomes (A6). (B) Example workflow outputs of tumour nuclei (B1), plasma cells
- 318 (B2), TILs (B3), nucleoli (B4) and tumour nuclear eccentricity (B5). (C) Example H&E images
- 319 from favourable (C1) and unfavourable (C2) outcome groups at 100x magnification. All scale
- 320 bars represent 150µm.

- 321 Figure 2. Heat map of all statistically significant variables using Euclidean distance and
- 322 hierarchical clustering by complete linkage. Patients are colour-coded based on outcome,
- 323 green representing favourable and magenta representing unfavourable outcomes
- 324 respectively.
- 325 Figure 3. (A) Boxplots of selected prognostic variables identified with the workflow. Values
- have been normalised within a range of 0 to 1. (B) The probability of each image being from
- 327 an UO patient as predicted by the neural network model, arranged from lowest to highest
- 328 probability when applied to the test set.
- 329 Table 1. Software used in the workflow and their respective functions.

No.	Software	Purpose
1.	QuPath	Pixel-level classification with an artificial neural network pixel classifier in-built in QuPath
2.	ImageJ	Unsharp mask for all images. Increasing minimum pixel intensities for faded slides. Renaming images for CellProfiler metadata.
3.	Stardist	Convolutional neural network for segmentation of clustered cells
4.	CellProfiler	Object-level segmentation. Feature measurements for supervised machine learning in CellProfiler Analyst. Single-cell quantification and measurements for cytomorphology spatial distribution, texture and granularity features.
5.	CellProfiler Analyst	Supervised machine learning for classification of different cell types with a Fast Gentle Boosting algorithm.
6.	RStudio	Univariate and multivariate data analysis. Training and validation of the prognostic neural network model.

330

331

332

333

334

335

	Favo	ourable outcome	Unfavourable outcome
Age (mean/range)	62 (4	48-80)	60 (47-78)
Male	e (n) 26		23
Fem	ale (n) 4		5
I-II (i Stage	n) 4		2
III-I\\	′ (n) 26		26

336 Table 2. Clinicopathologic features of the patient cohort.

337

- 338 Table 3. Univariate Wilcoxon's rank sum test and multivariable logistic regression analyses
- 339 for all 34 analysed variables compared between favourable and unfavourable outcome
- 340 groups. Statistical significance accepted at *P*<0.05.

		Favourable	Favourable	Unfavourable	Unfavourable	Univariable Wilcoxon rank sum	Multivariable Logistic Regression
	Variable	Median	IQR	Median	IQR	test P	Р
=	TIL Index	11.31	22.24	3.16	10.78	<0.001	0.0074
Immune Cell	Intratumour TILs (n)	24	38	9	22	<0.001	0.5075
aur	Stromal TILs (n)	35	71.5	11	43	<0.001	0.0073
Jur	Total TILs (n)	62.5	114.75	25	64	<0.001	0.662
<u>2</u>	Plasma Cells (n)	65	97.25	23	53.5	<0.001	0.002
	Texture	03	97.25	21	55.5	<0.001	0.0082
	Correlation	0.1452	0.077	0.0998	0.0821	<0.001	0.279
e & arity	Texture Entropy	9.7	0.39	9.68	0.45	<0.001	0.0068
Texture & Granularity	Texture						
ex irar	InfoMeas1	0.9957	0.0037	0.9951	0.0046	0.017	0.2359
- Q	Granularity 7	4.76	3.91	3.89	3.77	0.002	0.0032
	Granularity 1	62.87	10.98	61.25	13.53	0.006	0.4221
<u>≥</u>	Form Factor	0.841	0.031	0.809	0.089	<0.001	0.8471
Tumour Nuclear Morphology	Compactness	1.21	0.06	1.28	0.2	<0.001	0.1878
Tumour Nuclear orpholoç	Eccentricity	0.718	0.039	0.733	0.043	<0.001	0.0018
L J Į	Perimeter (Px)	98.37	12.05	100.65	10.73	0.0052	0.0096
2	Cell Area (Px)	643.02	190.29	658.77	189.53	0.0821	0.0631
Fumour Cell Spatial Distribution	Number of Neighbours	5.81	0.03	5.8	0.05	<0.001	0.2811
mour C Spatial stributic	1st Neighbour			_			
stri	Distance (Px)	36.63	4.2	37.55	6.68	<0.001	<0.001
<u>D</u> <u>D</u>	2nd Neighbour Distance (Px)	47.37	6.91	49.16	11.05	<0.001	<0.001
(0	Tumour Cell	47.37	0.91	49.10	11.05	<0.001	<0.001
er our ires	Count	1449.5	474.75	1334	590.5	<0.001	0.0874
Other Tumour Features	Image Nucleoli	404.5	341.75	334	269	<0.001	0.3394
Ϋ́́⊢Ψ	Nucleoli Ratio	0.269	0.246	0.27	0.203	0.0311	0.4019
	Texture Correlation	0.449	0.141	0.399	0.205	<0.001	0.0232
	Texture Entropy	0.219	0.139	0.305	0.256	<0.001	0.9846
	Texture						
īž	InfoMeas1	1.03E-02	2.12E-02	0.0158	0.03	0.0011	0.4841
ene	Granularity 7	0.0571	0.0894	0.032	0.1114	0.0016	0.0067
oge	Granularity 1	0.234	0.18	0.262	0.278	0.0791	0.0172
tere	Form Factor	0.147	0.202	0.343	0.432	<0.001	0.0091
He	Compactness	0.0292	0.0442	0.078	0.1286	<0.001	0.9956
JUL	Eccentricity	0.483	0.212	0.496	0.181	0.1735	0.1382
j mc	Perimeter	0.129	0.088	0.186	0.221	<0.001	0.001
a-tu	Cell Area	0.187	0.175	0.207	0.19	0.0012	0.0089
Intra-tumour Heterogeneity	Number of Neighbours	0.334	0.195	0.414	0.31	<0.001	0.1339
	1st Neighbour Distance	0.0604	0.055	0.0745	0.0829	<0.001	0.046
	2nd Neighbour Distance	0.0516	0.0517	0.0615	0.0613	0.0056	0.1434

## 341 References

- 3421.Pytynia KB, Dahlstrom KR, Sturgis EM. Epidemiology of HPV-associated343oropharyngeal cancer. Oral Oncol. 2014;50(5):380-386.
- Zhang Y, Fakhry C, D'Souza G. Projected Association of Human
   Papillomavirus Vaccination With Oropharynx Cancer Incidence in the US,
   2020-2045. *JAMA Oncol.* 2021;7(10):e212907.
- Liu HW, Li JT, Zhou YB, Hu Q, Zeng Y, Mohammadreza MM. Human
   Papillomavirus as a Favorable Prognostic Factor in a Subset of Head and
   Neck Squamous Cell Carcinomas: A Meta-Analysis. *J Med Virol.* 2017;89(4):710-725.
- Golusinski P, Corry J, Poorten VV, et al. De-escalation studies in HPV positive oropharyngeal cancer: How should we proceed? *Oral Oncol.* 2021;123:105620.
- 3545.Masterson L, Moualed D, Liu ZW, et al. De-escalation treatment protocols for355human papillomavirus-associated oropharyngeal squamous cell carcinoma: a356systematic review and meta-analysis of current clinical trials. Eur J Cancer.3572014;50(15):2636-2648.
- Mirghani H, Blanchard P. Treatment de-escalation for HPV-driven
   oropharyngeal cancer: Where do we stand? *Clin Transl Radiat Oncol.* 2018;8:4-11.
- 361 7. Gorphe P, Classe M, Ammari S, et al. Patterns of disease events and causes
  362 of death in patients with HPV-positive versus HPV-negative oropharyngeal
  363 carcinoma. *Radiother Oncol.* 2022;168:40-45.
- Westra WH. The Morphologic Profile of HPV-Related Head and Neck
   Squamous Carcinoma: Implications for Diagnosis, Prognosis, and Clinical
   Management. *Head and Neck Pathology.* 2012;6(1):48-54.
- Lewis JS, Jr., Scantlebury JB, Luo J, Thorstad WL. Tumor Cell Anaplasia and Multinucleation Are Predictors of Disease Recurrence in Oropharyngeal Squamous Cell Carcinoma, Including Among Just the Human Papillomavirus-Related Cancers. *The American Journal of Surgical Pathology*. 2012;36(7).
- Ruangritchankul K, Sandison A, Warburton F, et al. Clinical evaluation of
  tumour-infiltrating lymphocytes as a prognostic factor in patients with human
  papillomavirus-associated oropharyngeal squamous cell carcinoma. *Histopathology.* 2019;75(1):146-150.
- Wieland A, Patel MR, Cardenas MA, et al. Defining HPV-specific B cell
  responses in patients with head and neck cancer. *Nature*.
  2021;597(7875):274-278.
- Gui S, O'Neill WQ, Teknos TN, Pan Q. Plasma cell marker, immunoglobulin J
  polypeptide, predicts early disease-specific mortality in HPV+ HNSCC. J *Immunother Cancer.* 2021;9(3).
- Gougousis S, Mouchtaropoulou E, Besli I, Vrochidis P, Skoumpas I,
   Constantinidis I. HPV-Related Oropharyngeal Cancer and Biomarkers Based
   on Epigenetics and Microbiome Profile. *Front Cell Dev Biol.* 2020;8:625330.

384 385 386	14.	Worsham MJ, Chen KM, Ghanem T, Stephen JK, Divine G. Epigenetic modulation of signal transduction pathways in HPV-associated HNSCC. <i>Otolaryngol Head Neck Surg.</i> 2013;149(3):409-416.
387 388	15.	Wu S, Zhu W, Thompson P, Hannun YA. Evaluating intrinsic and non-intrinsic cancer risk factors. <i>Nature Communications.</i> 2018;9(1):3490.
389 390 391 392	16.	Excellence NIfHaC. Cancer of the upper aerodigestive tract: assessment and management in people aged 16 and over. <u>https://www.nice.org.uk/guidance/ng36/chapter/Recommendations#hpvrelate</u> <u>d-disease</u> . Published 2016. Updated 06 June 2018. Accessed.
393 394	17.	Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: an open-source platform for biological-image analysis. <i>Nat Methods.</i> 2012;9(7):676-682.
395 396	18.	Bankhead P, Loughrey MB, Fernandez JA, et al. QuPath: Open source software for digital pathology image analysis. <i>Sci Rep.</i> 2017;7(1):16878.
397 398	19.	Schmidt U, Weigert M, Broaddus C, Myers G. Cell Detection with Star-Convex Polygons. 2018; Cham.
399 400	20.	McQuin C, Goodman A, Chernyshev V, et al. CellProfiler 3.0: Next-generation image processing for biology. <i>PLoS Biol.</i> 2018;16(7):e2005970.
401 402 403	21.	Jones TR, Kang IH, Wheeler DB, et al. CellProfiler Analyst: data exploration and analysis software for complex image-based screens. <i>BMC Bioinformatics</i> . 2008;9(1):482.
404 405	22.	Fleiss JL CJ, Everitt BS. Large sample standard errors of kappa and weighted kappa. <i>Psychological Bulletin.</i> 1969;72(5):323-327.
406 407 408	23.	Echle A, Rindtorff NT, Brinker TJ, Luedde T, Pearson AT, Kather JN. Deep learning in cancer pathology: a new generation of clinical biomarkers. <i>British Journal of Cancer.</i> 2021;124(4):686-696.
409 410 411 412 413 414 415 416	24.	Hendry S, Salgado R, Gevaert T, et al. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. <i>Adv Anat Pathol.</i> 2017;24(6):311-335.
417 418 419	25.	Kim SS, Shen S, Miyauchi S, et al. B Cells Improve Overall Survival in HPV- Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade. <i>Clinical Cancer Research</i> . 2020;26(13):3345.
420 421 422 423 424	26.	Lewis JS, Jr., Scantlebury JB, Luo J, Thorstad WL. Tumor cell anaplasia and multinucleation are predictors of disease recurrence in oropharyngeal squamous cell carcinoma, including among just the human papillomavirus-related cancers. <i>The American journal of surgical pathology.</i> 2012;36(7):1036-1046.
425 426 427	27.	Ali S, Lewis J, Madabhushi A. Spatially aware cell cluster(spACC1) graphs: predicting outcome in oropharyngeal pl6+ tumors. <i>Med Image Comput Comput Assist Interv.</i> 2013;16(Pt 1):412-419.

- 428 28. Delides A, Panayiotides I, Alegakis A, et al. Fractal dimension as a prognostic
  429 factor for laryngeal carcinoma. *Anticancer Res.* 2005;25(3b):2141-2144.
- 430 29. Axelrod DE, Miller NA, Lickley HL, et al. Effect of Quantitative Nuclear Image
  431 Features on Recurrence of Ductal Carcinoma In Situ (DCIS) of the Breast.
  432 Cancer Informatics. 2008;6:CIN.S401.
- 433 30. Orsolic I, Jurada D, Pullen N, Oren M, Eliopoulos AG, Volarevic S. The
  434 relationship between the nucleolus and cancer: Current evidence and
  435 emerging paradigms. *Seminars in Cancer Biology*. 2016;37-38:36-50.
- 436 31. Stępiński D. The nucleolus, an ally, and an enemy of cancer cells. *Histochem* 437 *Cell Biol.* 2018;150(6):607-629.

438





